Web Images Videos Maps News Shopping Gmail more »
Sign in
Scholar Home  
  Advanced Scholar Search
Scholar Preferences
Scholar Results 1 - 10 of 12 citing Lopes-Virella: Role of simvastatin as an immunomodulator in type 2 diabetes. (0.14 sec) 

Reduction of oxidative stress and modulation of autoantibodies against modified low-density …


U Resch, F Tatzber, A Budinsky, H Sinzinger - British journal of clinical pharmacology, 2006 - pubmedcentral.nih.gov
This was an open-label study of patients in Austria receiving 10 or 40 mg
rosuvastatin daily alternately during 12 and 24 weeks. Circulating
concentrations of antibodies to malondialdehyde-oxidized LDL (MDA-LDL), ...
Cited by 35 - Related articles - BL Direct - All 9 versions

Atherogenesis and the humoral immune response to modified lipoproteins

- nih.gov
G Virella, MF Lopes-Virella - Atherosclerosis, 2008 - Elsevier
Modified forms of LDL are immunogenic and activate both cell-mediated and
humoral immune responses. Both types of responses are pro-inflammatory and are
probably primary players in the perpetuation of the chronic inflammatory ...
Cited by 5 - Related articles - All 36 versions

Simvastatin: two decades in a circle


GD Kolovou, A Katerina, V Ioannis, DV … - Cardiovascular Therapeutics, 2008 - interscience.wiley.com
Simvastatin is an agent of the 3-hydroxy-3-methylglutaryl coenzyme A reductase
inhibitor group of drugs. It is administrated orally once a day in doses of
5–80 mg. Although its main action is to reduce total and low-density ...
Cited by 4 - Related articles - BL Direct - All 2 versions

Simvastatin down regulates mRNA expression of RANTES and CCR5 in posttransplant renal …


Q Li, D Wang, Y Wang, Q Xu - Transplantation proceedings, 2006 - Elsevier
Chemokines and hyperlipidemia are involved in the mechanism of chronic allograft
nephropathy (CAN). In this study, the mRNA expression of RANTES and its receptor
CCR5 on peripheral blood mononuclear cells were measured in renal ...
Cited by 1 - Related articles - All 14 versions

高脂血症肾移植患者外周血 MCP-1 及其受体 CCR2 mRNA 表达及辛伐他汀治疗的影响


王玉新, 史艳玲, 李清芹, 邹和群, 徐琴君, 唐 … - 中山大学学报: 医学科学版, 2005 - cqvip.com
首页; 期刊导航; 知识社区; 学者空间; 学术机构; 专题导读;
充值中心; 论文翻译. 登录 注册 帮助. 维普资讯 ...
Cited by 1 - Related articles - All 4 versions

Clinical significance of the humoral immune response to modified LDL


MF Lopes-Virella, G Virella - Clinical Immunology, 2009 - Elsevier
Human low density lipoprotein (LDL) undergoes oxidation and glycation in vivo.
By themselves, oxidized LDL (oxLDL) and AGE-LDL have proinflammatory properties
and are considered atherogenic. But the atherogenicity of these ...
Related articles - All 2 versions

[PDF] Effects of statins on liver fibrosis reversibility and activities of lysosomal exoglycosidases


… , M Knas2ABCDEF, D Dudzik2BF, M Borzym … - academpharm.by
Background: Liver fibrosis is a spontaneously reversible process occurring
predominantly after withdrawal of fibrogenic agents. We tested statins as
promising antifibrotic agents using an experimental model of thioacetamide ...
Related articles - View as HTML

Role of Simvastatin as an Immunomodulator in Type 2 Diabetes

- diabetesjournals.org [PDF] 
M Petrou, M Gregoriades, V Vassiliou - Diabetes care, 2004 - Am Diabetes Assoc
A Medline search performed on 24 April 2004 for the incorrect term “creatinine
kinase” revealed a total of 356 entries. Organizing these entries according to
which decade they were published, we could see that from 1964 to 1974 there ...
Related articles - BL Direct - All 5 versions

[DOC] GABRIEL VIRELLA, MD, Ph. D.


P STATISTICS, B CERTIFICATION, MINS … - academicdepartments.musc.edu
CURRICULUM VITAE. GABRIEL VIRELLA, MD, Ph.D. PERSONAL STATISTICS. Date of
Birth: May 23, 1943 Nationality: US Citizen. Place of Birth ...
Related articles - View as HTML

[CITATION] STATINOTERAPIA INTENSIVÃ


CC de Diabet, BMCN Nutriþie, C de Diabet, …
Related articles


Result Page: 

1

2

Next


 


Go to Google Home - About Google - About Google Scholar

©2009 Google